AC Immune Acquires Experimental Vaccine PD01, Other Therapies

AC Immune Acquires Experimental Vaccine PD01, Other Therapies

300883

AC Immune Acquires Experimental Vaccine PD01, Other Therapies

Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC Immune in a recent deal valued at nearly $60 million. “We believe very strongly that active vaccination will play an important role in the long-term management and possible prevention of neurodegenerative diseases,” Andrea Pfeifer, PhD, CEO of AC Immune, said in a press release announcing the pharmaceutical’s acquisition of the Affiris therapies. “By acquiring a clinically validated…

You must be logged in to read/download the full post.